Jinfeng Wu

Jan 9, 2025 | onlinelibrary.wiley.com | Haihong Qin |Zheng Li |Jinfeng Wu |Xiao Qiang Liu

Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description cep70022-sup-0001-FigureS1.tifTIFF image, 9.7 MB Figure S1. Toxicity of cells with different drug treatment in two melanoma cell lines SK-MEL-5R and A375R. Toxicity of cells in SK-MEL-5R cells (A) and A375R cells (B) following different drug treatment. The cytotoxicity(%) was the relative value to medium-only group with cytotoxicity as 0. *PLX + DI group vs.

Aug 27, 2024 | nature.com | Jinfeng Wu

AbstractAlthough overall survival data are still premature, the PROpel study found radiological progression-free survival (PFS) benefits of abiraterone and olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). However, for patients who have not been genetically tested or lack BRCA1/2 mutations (BRCAm), this combination therapy has been questioned as a first-line conventional treatment for mCRPC, mainly due to significant health economics and side effects.

Jun 11, 2024 | nature.com | Yang Chen |Xingwu Jiang |Jinfeng Wu |Bin Zheng |Dayong Jin

AbstractTo fulfil the demands of rapid proliferation, tumour cells undergo significant metabolic alterations. Suppression of hyperactivated metabolism has been proven to counteract tumour growth. However, whether the reactivation of downregulated metabolic pathways has therapeutic effects remains unexplored. Here we report a nutrient-based metabolic reactivation strategy for effective melanoma treatment.